Nanotools for sepsis diagnosis and treatment
Papafilippou, Lana (The University of Manchester. Faculty of Biology, Medicine and Health)
Claxton, Andrew (Salford Royal Foundation Trust. Department of Critical Care)
Dark, Paul (Manchester NIHR Biomedical Research Centre)
Kostarelos, Kostas (Institut Català de Nanociència i Nanotecnologia)
Hadjidemetriou, Marilena (The University of Manchester. Faculty of Biology, Medicine and Health)

Data:	2021
Resum:	Sepsis is one of the leading causes of death worldwide with high mortality rates and a pathological complexity hindering early and accurate diagnosis. Today, laboratory culture tests are the epitome of pathogen recognition in sepsis. However, their consistency remains an issue of controversy with false negative results often observed. Clinically used blood markers, C reactive protein (CRP) and procalcitonin (PCT) are indicators of an acute-phase response and thus lack specificity, offering limited diagnostic efficacy. In addition to poor diagnosis, inefficient drug delivery and the increasing prevalence of antibiotic-resistant microorganisms constitute significant barriers in antibiotic stewardship and impede effective therapy. These challenges have prompted the exploration for alternative strategies that pursue accurate diagnosis and effective treatment. Nanomaterials are examined for both diagnostic and therapeutic purposes in sepsis. The nanoparticle (NP)-enabled capture of sepsis causative agents and/or sepsis biomarkers in biofluids can revolutionize sepsis diagnosis. From the therapeutic point of view, currently existing nanoscale drug delivery systems have proven to be excellent allies in targeted therapy, while many other nanotherapeutic applications are envisioned. Herein, the most relevant applications of nanomedicine for the diagnosis, prognosis, and treatment of sepsis is reviewed, providing a critical assessment of their potentiality for clinical translation.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Diagnosis ; Nanotechnology ; Nanotheranostics ; Sepsis ; Treatment
Publicat a:	Advanced Healthcare Materials, Vol. 10, issue 1 (Jan. 2021) , art. 2001378, ISSN 2192-2659

DOI: 10.1002/adhm.202001378
PMID: 33236524

26 p, 4.7 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències > Institut Català de Nanociència i Nanotecnologia (ICN2)
Articles > Articles de recerca
Articles > Articles publicats